Cell Genesys is focused on the development
and commercialization of novel biological therapies for
patients with cancer. The company has a broad portfolio of
clinical stage product development programs, an extensive
technology and patent estate, and a strong balance sheet.
The company is conducting clinical trials in multiple types
of cancer utilizing two of its three product platform
technologies--GVAX® cancer vaccines and oncolytic virus
therapies.
